Business Wire

Panasonic Is Holding Its Special Exhibition "The Moment" Officially Approved by the French Embassy in Japan

Del

Panasonic Corporation is holding "The Moment" from October 2 to December 2, 2018. This is a special exhibition authorized as a project to celebrate the 160th anniversary of the establishment of diplomatic relations between France and Japan at the Panasonic Center Tokyo (3-5-1 Ariake, Koto-ku, Tokyo). This exhibition is the second round for FY2018 of the“Let's Build Tokyo Together”(*) interactive activity project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181002005420/en/

Exhibits - "The Moment - Artistic way of looking at sports" (Photo: Business Wire)

Exhibits - "The Moment - Artistic way of looking at sports" (Photo: Business Wire)

It is a photographic exhibition with a primary focus on culture. The French duo Audic-Rizk, who has artistic roots in Tokyo, is expressing athletes' vitality to the max in photos and highlights their crowning moments with Panasonic's projector called Space Player. The event is also offering activities based on the theme "Sports X Photos."
Through the exhibition sponsored by the French Embassy in Japan and other organizations, Panasonic will further boost cultural exchanges between France and Japan commemorating the 160th anniversary of the establishment of diplomatic relations between the two countries, and globally communicate the attractiveness of sports toward the Tokyo 2020 Games and the Paris 2024 Games through photographic artwork as a Worldwide Olympic Partner and Worldwide Paralympic Partner.

Panasonic will continue to contribute to fostering the Olympic and Paralympic Movement through these global initiatives.

[Profile of the exhibiting artist Audic-Rizk]
Audic-Rizk is French artist duo formed by photographers Julie Audic and Christian Rizk. They studied in Japan for five years from 1998 and 2000 respectively as laureates of the Research Student Program scholarship awarded by the Ministry of Education, Culture, Sports, Science and Technology. They have developed artwork based on a photographic technique that they call "Intensive Photography," which does not involve any retouching or digital manipulation. With the reflection of atmospheric colors affected by light or humidity during the shooting process, their photos capture the dynamic intensities and motions of sports and athletes as works of art.

*   Authorized as part of the Tokyo 2020 Official Programme, the “Let's Build Tokyo Together” project promotes a wide range of activities featuring sports, culture, and education until 2020 bringing together children and young people, who will become major players in the next generation, with an eye on handing over our heritage to the Tokyo of the future with the participation of as many individuals as possible.
 

"The Moment - Artistic way of looking at sports" exhibition overview

-  

Period:

October 2 - December 2, 2018 * Closed on Mondays

-

Open:

10:00 a.m. - 6:00 p.m. (last admission: 5:45 p.m.)

-

Venue:

Panasonic Center Tokyo (3-5-1 Ariake, Koto-ku, Tokyo)

- Access:

https://www.panasonic.com/global/corporate/center/tokyo/access.html

Two minutes' walk from Kokusai-Tenjijo Station on Rinkai Line
Three minutes' walk from Ariake Station on Yurikamome Line
- Admission: Free
- Organized by: Panasonic Corporation
- With the cooperation of:
The Tokyo Organising Committee of the Olympic and Paralympic Games
- Under the auspices of:
Embassy of France in Japan / Institut français du Japon
Japanese Olympic Committee
Japanese Para-Sports Association Japanese Paralympic Committee
 

[Related activities]
Date: October 27 (PM)
Contents: Workshop and exhibition tour with AUDICRIZK
Target: Elementary and junior high school students

Date: October 28 (PM)
Contents: Workshop and exhibition tour with AUDICRIZK
Target: Adults

For more information about the related activities, please check the event page on Panasonic Center Tokyo’s website.
URL : https://www.panasonic.com/global/corporate/center/tokyo.html

Source:
https://news.panasonic.com/global/topics/2018/61633.html

Related Links
Panasonic Center Tokyo
https://www.panasonic.com/global/corporate/center/tokyo.html

Panasonic Center Osaka
https://www.panasonic.com/global/corporate/center/osaka.html

Panasonic Official Olympic Website "Sharing the Passion"
https://www.panasonic.com/global/olympic.html

Panasonic's Audio Visual Solutions for Professionals
https://panasonic.net/cns/mebd/

Panasonic Delivers a Wide Range of Solutions and Equipment for Staging the Olympic Winter Games PyeongChang 2018 (Feb 12, 2018)
https://news.panasonic.com/global/topics/2018/54669.html

Related Videos:
Pyeongchang 2018 Winter Olympic and Paralympic Games Cheering Stadium
https://youtu.be/6f2kOn9Vqkk
Let's Build Tokyo Together - Special Exhibition "The Passions"
https://youtu.be/GCy5xCXh3hg

Contact information

Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 16:00:00 CESTPressemelding

Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo

MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 15:58:00 CESTPressemelding

The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha

EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 15:32:00 CESTPressemelding

EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,

Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 15:00:00 CESTPressemelding

Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc

Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 14:40:00 CESTPressemelding

Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 13:15:00 CESTPressemelding

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava